Taken together, we demonstrated that the mechanism of glutamine strengthens the antioxidant capacity in PC12 cells induced by MPP+ via inhibiting the activation of the PI3K/Akt signaling pathway, potentially offering new molecular targets for treatment of PD. This evidence concerns the gene AKT1 and Parkinson disease.